Safety in Japanese Advanced Breast Cancer Patients Who Received Abemaciclib in MONARCH 2 and MONARCH 3: Assessment of Treatment-Emergent Neutropenia, Diarrhea, and Increased Alanine Aminotransferase and Aspartate Aminotransferase Levels.

Norikazu MasudaYucherng ChenTsutomu KawaguchiKoji DozonoMasakazu Toi

Published in: Cancer management and research (2022)

Abemaciclib was well tolerated in Japanese patients in MONARCH 2 and MONARCH 3, with common, clinically relevant TEAEs manageable with appropriate interventions.

Keyphrases

physical activity
irritable bowel syndrome
combination therapy
replacement therapy
smoking cessation